{
    "title": "AstraZeneca gains 5% on marketing nod to launch cancer drug in India",
    "link": "https://www.business-standard.com/article/markets/astrazeneca-gains-5-on-marketing-nod-to-launch-cancer-drug-in-india-118062200195_1.html",
    "pubDate": "Fri, 22 Jun 2018 10:00:00 +0530",
    "content": "The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.",
    "contentSnippet": "The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.",
    "guid": "https://www.business-standard.com/article/markets/astrazeneca-gains-5-on-marketing-nod-to-launch-cancer-drug-in-india-118062200195_1.html",
    "isoDate": "2018-06-22T04:30:00.000Z",
    "sentiment": {
        "score": 1,
        "comparative": 0.08333333333333333,
        "tokens": [
            "astrazeneca",
            "gains",
            "5",
            "on",
            "marketing",
            "nod",
            "to",
            "launch",
            "cancer",
            "drug",
            "in",
            "india"
        ],
        "words": [
            "cancer",
            "gains"
        ],
        "positive": [
            "gains"
        ],
        "negative": [
            "cancer"
        ]
    },
    "article": {
        "title": "AstraZeneca gains 5% on marketing nod to launch cancer drug in India",
        "content": "<div class=\"content-main\" id=\"hpcontentbox\"><span>\n\t    \n  </span><!-- /Dynamic Banner 1 mytest_728x90 --><span>\n</span><p>\n\n<style type=\"text/css\">.banner-970-90:first-child{display:none}#dynamicBanner1{margin:0 auto;width:728px;margin-bottom:21px}</style>\n</p><span>\n  </span><!-- /Dynamic Banner 1 mytest_728x90 --><span>\t\t\n\t\t\n\t\t</span><link href=\"https://bsmedia.business-standard.com/include/_mod/site/html5/css/arrow.css\" rel=\"stylesheet\" type=\"text/css\"><span>\n</span><link href=\"https://bsmedia.business-standard.com/include/_mod/site/html5/css/article.main.css?2046\" rel=\"stylesheet\" type=\"text/css\"><span>\n\n</span><!-- Move Video Embed code Top if Exist Start --><span>\n</span><!-- Move Video Embed code Top if Exist End --><span>\n\n</span><meta itemprop=\"keywords\" name=\"keywords\" content=\"AstraZeneca Pharma India, Markets, Durvalumab\"><span>\n\n</span><style type=\"text/css\">body#cke_pastebin{position:inherit!important;top:inherit!important;width:inherit!important;height:inherit!important;overflow:inherit!important;left:inherit!important}span.p-content{font-family:'Open Sans',sans-serif;font-size:15px;line-height:24px}span.p-content a{color:#2591dc;text-decoration:none}.bBorder1{border-bottom:1px solid #c4c6c8!important}li.size16 .bB1:last-child{border-bottom:0!important}.colL_MktColumn1.panel-left .banner240-180 div[style=\"float: left;\"] div[style=\"float: left; clear: both; font-style:italic; padding: 10px 10px 10px 0px; width:620px;\"]{width:100%!important}.unlock_bg{padding:8px 15px;height:44px;background:#eee none repeat scroll 0% 0%;border-width:1px 1px 1px 4px;border-style:solid;border-color:#fff #fff #fff #ac2122;box-shadow:0 0 10px 0 #d6d6d6;font-family:\"Open Sans\",sans-serif;font-size:16px;color:#1d1d1d;font-weight:600;width:640px}.unlock_bg ul{margin:0;padding:0}.unlock_bg ul li{list-style-type:none;float:left}.unlock_bg .unlock{padding:3px 0 0 10px;vertical-align:middle}.unlock_bg .unlock a{text-decoration:none;color:#1d1d1d}.unlock_bg .circle{width:22px;height:22px;background-color:#ac2122;-moz-border-radius:70px;-webkit-border-radius:70px;border-radius:70px;text-align:center;color:#fff;margin-left:45px;margin-top:3px}.unlock_bg .article{padding:3px 0 0 10px;vertical-align:middle;color:#017e22}.unlock_bg .article a{text-decoration:none;color:#017e22}.columnist{padding:6px 10px;border:0;display:block;background:#4d5557;color:#fff;font-size:14px;cursor:pointer}.modal{opacity:0;visibility:hidden;position:fixed;top:0;right:0;bottom:0;left:0;text-align:left;transition:opacity .25s ease;z-index:999;position:relative}.modal__bg{position:relative;top:0;right:0;bottom:0;left:0;cursor:pointer}.modal-state{display:none}.modal-state:checked+.modal{opacity:1;visibility:visible}.modal-state:checked+.modal .modal__inner{top:0}.modal__inner{transition:top .25s ease;position:relative;top:0;right:0;bottom:0;left:0;width:640px;margin:auto;overflow:auto;background:#eee;padding:10px 15px;height:70px;border-top:1px solid #fff;border-right:1px solid #fff;border-bottom:1px solid #fff;border-left:4px solid #ac2122;-webkit-box-shadow:0 0 10px 0 rgba(214,214,214,1);-moz-box-shadow:0 0 10px 0 rgba(214,214,214,1);box-shadow:0 0 10px 0 rgba(214,214,214,1);font-family:'Open Sans',sans-serif;font-size:15px;color:#1d1d1d;line-height:22px}.modal__inner_left{width:70%;float:left}.modal__inner_right{width:30%;float:right}.modal__close{position:absolute;right:10px;top:20px;width:70px;height:24px;cursor:pointer;background-color:#ac2122;font-size:13px;font-weight:normal;border-radius:2px;text-align:center;color:#fff}.modal__proceed{position:absolute;right:90px;top:20px;width:70px;height:24px;cursor:pointer;background-color:#0a6d02;font-size:13px;font-weight:normal;border-radius:2px;text-align:center;color:#fff}@media (max-width:768px){.modal__inner{width:692px}.floatR{float:right!important}.unlock_bg{width:692px}}</style><span>\n</span><!-- Subscription band - Start --><span>\n</span><!-- Subscription band - End --><span>\n</span><!-- Go to www.addthis.com/dashboard to customize your tools --><span>\n\n</span><span>\n\n\n\t  \t\t\t\t\t\t</span><!-- ADV 728X90 --><span>\n\t\t\t</span><span>\n\t\t\n\t  \t   \t\t  \t\t    \t\t</span><a href=\"https://plus.google.com/105513640026823338822?rel=author\">Business Standard</a><span>\n  \t\t\n\t</span><!-- row-panel --><span>\n    </span><div class=\"row-panel\"><span>\n\t\t</span><!-- breadcrum --><span>\n        \t   \n\t   </span><meta itemprop=\"sourceOrganization\" content=\"Business-Standard\"><span>\n\t   </span><meta itemprop=\"publisher\" content=\"Business-Standard\"><span>\n\t   \n        </span><!-- breadcrum end --><span>\n      \t</span><!-- LEFT CONTENT --><span>\n      \t        </span><div class=\" main-cont-left topB\"><span>\n\t\t\t</span><div class=\"row-inner\"><span>\n\t        \t</span><!-- TOP ARTICLE HEAD  --><span>\n\t          \t</span><div class=\"story-head pB0\"><span>\n\t\t\t\t\t  \t\t\t\t\t  \n\t\t\t\t\t </span><span>\n\t\t\t\t  \t\t\t\t\t   \t\t</span><h2 class=\"alternativeHeadline\">The stock was up 5% to Rs 1,416 after the company said it has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.</h2><span>\n\t\t\t\t   \t\n\t\t\t\t\t</span><!-- LAST UPDATE --><span>\n\t\t\t\t\t</span><div class=\"last-update mT10\"><span>\n\t\t\t\t\t\t  </span><p class=\"fL\">\n\t\t\t\t\t\t\t  <span>\n\t\t\t\t\t\t\t\t  \t\t\t\t\t\t\t\t  <a target=\"_blank\" href=\"https://www.business-standard.com/author/search/keyword/si-reporter\">SI Reporter</a>&nbsp;\t\t\t\t\t\t\t\t  \t\t\t\t\t\t\t\t  |&nbsp;\n\t\t\t\t\t\t\t\t  \t\t\t\t\t\t\t\t  \t\t\t\t\t\t\t\t  <news:geo_locations>Mumbai</news:geo_locations>&nbsp;\t\t\t\t\t\t\t  </span>\n\t\t\t\t\t\t\t  \t\t\t\t\t\t\t  <meta itemprop=\"datePublished\" content=\"2018-06-22\">\n\t\t\t\t\t\t\t  <span itemprop=\"datePublished\" content=\"2018-06-22\">\t\t\t\t\t\t\t  Last Updated at June 22, 2018 10:05 IST</span>\n\t\t\t\t\t\t\t  \t\t\t\t\t\t</p><span>\n\t\t\t\t\t  \t\n\n\t\t\t\t\t\t\t\t\t\t\t      </span><span>\n\t\t\t\t\t   \n\t\t\t\t\t   \t\t\t\t\t   \n\t\t\t\t\t</span><span>\n\t\t\t\t\t</span></div><span>\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t</span><span>\n\t\t\t\t\t\t\t\t\t\t </span><span>\n\t\t\t\t\t</span><span>\n\t\t\t\t\t \t\t\t\t</span></div><span>\n\n\n\t\t       \t</span><!-- TXT ADV PANEL --><span>\n\t\t\t\t\t\t\t\t</span><!-- TXT ADV PANEL --><span>\n\t\t\t\t\t</span><span>\n\t\t\t\t\n\n        </span><!-- TOP ARTICLE CONTENT   --><span>\n \t\t\t\t\t\t\t\t\t</span><!-- Move Video Embed code Top if Exist Start --><span>\n\t\t\t\t\t\t\t\t\t\t</span><!-- STORY CONTENT --><span>\n  \t\t\t\t\t\t\t\t\t\t  \t\t\t\t\t\t</span><div class=\"colL_MktColumn0 full-img bB1\"><span>\n   \t \t\t\t\t\t\t</span><div><span>\n\t\t</span><img align=\"\" alt=\"pharma companies, immunology,vantage point, hospitals,science pharmaceuticals\" class=\"imgCont\" height=\"464\" src=\"https://bsmedia.business-standard.com/_media/bs/img/article/2018-01/14/full/1515953323-8176.jpg\" title=\"pharma companies, immunology,vantage point, hospitals,science pharmaceuticals\" width=\"620\"><span>\n\t\t</span><p>\n\t\t\tPatients prefer better outcome to brand in new treatments, says report</p><span>\n\t</span></div><span>\t   \t \t\t\t\t\t\t\t\t\t\t\t\t\t   \t </span><span>\n\t \t\t\t\t\t\t\t \t\t\t\t\t</span></div><span>\n\t \t\t\t\t\t</span><span>\n\t \t\t\t\t\t\t \t\t\t\t\t\t\t\t\t\t\t\t\t</span><div class=\"story-content\"><span>\n\t\t\t\t\n  \t\t\t\t\n  \t\t\t\t\t  \t\t\t\t\t      \t\t\t\t\t      \t\t\t\t\t\t   \t\t\t\t\t   \t\t\t\t\t   \t\t\t\t\t\n   \t\t\t\t\t</span><!-- Overwrite Story Content --><span>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t</span><style type=\"text/css\">.story-content span,.story-content p,.story-content div{color:#000!important;font-family:'open sans',Arial!important;font-size:15px!important}</style><span>\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t</span><!-- Overwrite Story Content --><span>\n\n\t\t\t\t     \t  \t\t\t\t\t\t\t</span><span>\n\t\t\t\t\t  \t\t\t\t\t\t\t\t\n\n\t            </span><span class=\"p-content\">\n\t            \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t    \t\t\t\t      <style>span.p-content div[id^=\"div-gpt\"]{line-height:0;font-size:0}</style>\n\t\t\t\t    \t<div><span>\n\t\n\t</span><a class=\"storyTags\" href=\"https://www.business-standard.com/topic/astrazeneca-pharma-india\" target=\"_blank\">AstraZeneca Pharma India </a><span>was up 5% to Rs 1,416 on the BSE in early morning trade after the company saidit has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine.</span><p>\n\t“The company has received import &amp; market permission for <a class=\"storyTags\" href=\"https://www.business-standard.com/search?type=news&amp;q=durvalumab\" target=\"_blank\">Durvalumab </a>(ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of <a class=\"storyTags\" href=\"https://www.business-standard.com/search?type=news&amp;q=durvalumab\" target=\"_blank\">durvalumab </a>(ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses,” <a class=\"storyTags\" href=\"https://www.business-standard.com/topic/astrazeneca-pharma-india\" target=\"_blank\">AstraZeneca Pharma India </a>said in a press release.\n\n\n</p><span>\n</span><!-- INPAGE_BANNER --><p>\n\t<a class=\"storyTags\" href=\"https://www.business-standard.com/search?type=news&amp;q=durvalumab\" target=\"_blank\">Durvalumab </a>provides a treatment option for patient with locally advanced, unresectable non-small cell lung cancer (NSCLC) and metastatic urothelial carcinoma. Durvalumab is a patented product of AstraZeneca global, it added.</p><p>\n\tThe company said Durvalumab is the only immunotherapy approved for patients with unresectable stage III non-small cell lung cancer (NSCLC). The medicine was granted US FDA ‘breakthrough therapy’ designation on July 31, 2017.</p><p>\n\tShares of AstraZeneca Pharma hit a 52-week high of Rs 1,515 on June 19, 2018 in intra-day trade, has rallied 21% in past two weeks. On comparison, the S&amp;P BSE Sensex was down 0.12% during the period.</p><p>\n\tAt 09:45 am; the stock was trading 3% higher at Rs 1,392 as compared to 0.22% decline in the benchmark index. A combined 133,393 shares changed hands on the BSE and NSE.</p></div>\n<br>\t\t\t\t\n\t\t\t\t    \t\t\t\t     \t            </span><span>\n\t           \n\t\t\t\t\t\t\t\t\t\t\t\t\n            </span><span>\n          </span><span>\n                  </span></div><span>\n\t\t\n\t\t\t\t\t  </span><p>\n\t\t\t  <style>.pubDate{color:#000!important;font-size:14px!important;border-top:solid 1px #cecece;font-style:italic;font-family:'open sans';padding:10px 0 2px 0}</style>\n\t\t\t\tFirst Published: Fri, June 22 2018. 10:00 IST\t\t\t\t</p><span>\n\t  \t\t\n        </span><!-- RELATED  CONTENT --><span>\n        </span><span>\n        \n        \t \t\n        </span><!-- RELATED  CONTENT end --><span>\n\t\t\t</span><div class=\"more-stories-pagination disNone\"><span>\n\t\t\t   </span><div class=\"row-inner\"><span>\n\t\t\t      </span><div class=\"nextprev-box\"><span>\n\t\t\t         </span><div class=\"NP-title\"><span>\n\t\t\t            </span><span class=\"col-2 Tcenter\">\n\t\t\t               <p>PREVIOUS STORY</p>\n\t\t\t            </span><span>\n\t\t\t            </span><span class=\"col-2 Tcenter\">\n\t\t\t               <p>NEXT STORY</p>\n\t\t\t            </span><span>\n\t\t\t            </span><span>\n\t\t\t         </span></div><span>\n\t\t\t         </span><a class=\"btn-control-left prev\"><img src=\"https://bsmedia.business-standard.com/include/_mod/site/html5/images/icon/prev-icon.jpg\"></a><span>  </span><a class=\"btn-control-right next\"><img src=\"https://bsmedia.business-standard.com/include/_mod/site/html5/images/icon/next-icon.jpg\"></a><span>\n\t\t\t         </span><span>\n\t\t\t         </span><span>\n\t\t\t      </span></div><span>\n\t\t\t   </span></div><span>\n\t\t\t</span></div><span>\n       </span><!-- RELATED TAB CONTENT END --><span>\n\n\n</span><!-- TXT ADV PANEL --><span>\n</span><!-- TXT ADV PANEL END --><span>\n\n      </span><!-- ADV 468X60 --><span>\n            \t</span><span>\n\t  \n </span><!-- TXT ADV PANEL --><span>\n         </span><span>\n        \n    </span><!-- This is Comment testing --><span>\n      </span><span>\n      \n      </span><!-- COMMNET BOX --><span>\n       </span><span>\n\n         </span></div><span>\n        </span></div><span>\n      </span><!-- LEFT CONTENT END --><span>\n\n\n     \t</span><!-- RIGHT CONTENT --><span>\n  \t\t</span><span>\n        </span><span>\n       </span><!-- RIGHT CONTENT END --><span>\n\n      \n      </span><!-- ADV 728X90 --><span>\n\t\t  \t\t  </span><span>\n\t\t  </span><span>\n\t\t      </span></div><span>\n\n</span><span>\n\n\n</span><span>\n\n</span><style type=\"text/css\">\n.articleCompanyStockInfo{display: none;}\n.bsNewArticleCompanyStockInfo{display: block;}\n#article-chart-39_article_ft{\n\tmargin-bottom: 40px;\n\tdisplay: block;\n\tpadding: 5px 30px;\n}\n});\n</style><span>\n\t</span><span>\n\n     \n </span><span>\n \n  \n </span><span>\n\n </span><span>\n    </span><!-- Change for Akamai's Start --><span>\n</span><span>\n</span><!-- Change for Akamai's Start --><span>\n</span><span id=\"readMoreSpanAjx\"></span><span>\n</span><span> </span></div>"
    },
    "adjectives": [
        "received",
        "stock",
        "General"
    ],
    "verbs": [
        "company",
        "market",
        "stock",
        "launch",
        "medicine",
        "nod",
        "drug",
        "Drug",
        "General"
    ],
    "nouns": [
        "company",
        "India",
        "marketing",
        "market",
        "Controller",
        "stock",
        "launch",
        "medicine",
        "approval",
        "nod",
        "cancer",
        "General",
        "treatment",
        "drug",
        "Drug"
    ]
}